The sales in the global patient-controlled injectors market are estimated to total US$ 3.5 Bn by 2022, exhibiting growth at a staggering CAGR of nearly 12% to 13% during the forecast period 2022-2032. The patient-controlled injectors market is expected to surpass US$ 8 Bn by the end of 2032, in comparison to the US$ 3 Bn registered in the year 2021. North America is estimated to emerge as the most remunerative market for patient-controlled injectors, accounting for around sales of US 3.5 Bn by 2032.
| Report Attribute | Details |
| Patient-Controlled Injectors Market Base Year Value (2021) | US$ 3 Billion |
| Patient-Controlled Injectors Market Expected Value (2022) | US$ 3.5 Billion |
| Patient-Controlled Injectors Market Anticipated Value (2032) | US$ 8 Billion |
| Patient-Controlled Injectors Market Projected Growth Rate (2022-2032) | 12% to 13% CAGR |
| Estimated North America Revenue Share in Patient-Controlled Injectors Market | US$ 3.5 Bn |
Patient-controlled injectors are a type of advanced drug delivery systems that is subcutaneously adhere to the body and dispense larger volumes (more than 2 mL) of a medical fluids or drug over an extended period.
Demand for patient-controlled injectors is anticipated to witness exponential growth, owing to increasing patient preference towards adopting advanced drug delivery solutions that offers greater comfort and ease of administration of injections.
On account of the technological advancement in medical technology, novel patient-controlled injectors enable patients to control the release of drugs, and decide their own dosage rate, along with helping them in administering injections by their own. A slew of such developments is projected to create growth opportunities in the coming years.
Although there are numerous benefits associated with the adoption of patient-controlled injectors, extravagant cost of these drug delivery solutions and high risk of compilations & irregular administration of drugs due to patient control are factor hamper the sales in the market.
Stringent regulatory standards, norms, and policies and time-consuming approvals process for the launch of new products are restraining the growth in the market.
North America is projected to account for the dominant share in the global patient-controlled injectors market during the forecast period 2022-2032, reveal FMI.
Due to increasing alcohol consumption, opioids-usage, obesity, a substantial rise in prevalence of chronic disorders such as cancer, autoimmune disorders, and blood disorders is being witnessed across North America, fueling demand for advanced drug delivery solutions.
According to the National Library of Medicine, nearly 45% of the population or more than 133 million people are suffering from at least one chronic condition across the U.S. Patient-controlled injectors are increasingly being adopted for the treatment of these diseases, favored by their ability to provide accurate dosages. Hence, the rising burden of these illnesses is expected to drive the growth in the North America market.
As per Future Market Insights, Western Europe is projected to exhibit robust growth in the global patient-controlled injectors market between 2022 and 2032.
Demand for advanced drug delivery solutions is surging at a rapid pace across Europe, driven by growing advancements in technology and rising adoption of new treatment options. Hence, prominent manufacturers are focusing on launching novel products to cater to this growing demand.
For instance, in 2019, Janseen, a pharmaceutical company headquartered in Belgium, announced introducing the first FDA-approved one-press patient-controlled injector, Tremfya, for the treatment of patients with Plaque Psoriasis. A multiplicity of such new product launches are anticipated to augment the sales in the Western Europe market.
Some of the leading players in the patient-controlled injectors market are West Pharmaceutical Services, Inc, Johnson and Johnson Services, Inc., Janssen Pharmaceutical, United Therapeutics Corporation, Westbourne Medical Ltd., SC Pharmaceuticals Inc., Gerresheimer AG, Hoffmann-La Roche Ltd., and others.
Prominent players are emphasizing on expanding their product portfolio and adopting collaboration, agreement, merger, and acquisition strategies to maintain their lead in the global market.
| Report Attribute | Details |
| Growth Rate | CAGR of 12% to 13% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Countries Covered |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product:
By Application:
By Distribution Channel:
By Region:
FMI projects the sales of patient-controlled injectors in the market is expected to rise at 12% to 13% value CAGR by 2032
The global patient-controlled injectors market is expected to be dominated by North America the forecast period 2022-2032.
West Pharmaceutical Services, Inc, Johnson and Johnson Services, Inc., Janssen Pharmaceutical, United Therapeutics Corporation, Westbourne Medical Ltd.,, SC Pharmaceuticals Inc., Gerresheimer AG, Hoffmann-La Roche Ltd., and others are some of the leading players in the prominent patient-controlled injectors market.
Explore Similar Insights
Patient-Controlled Injectors Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
